News | September 24, 2025
Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Subscribe To Our Newsletter & Stay Updated
